[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transplant-complication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transplant-complication":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,42,68,95,124,153,175,200,229],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100622252","assessing-the-incidence-of-transplant-associated-thrombotic-microangiopathy-ta-tma-in-adult-patients-undergoing-allogeneic-stem-cell-transplant-sct-100622252",false,"NCT07381205","Assessing the Incidence of Transplant Associated Thrombotic Microangiopathy (TA-TMA) in Adult Patients Undergoing Allogeneic Stem Cell Transplant (SCT)","Prospective Evaluation of Transplant Associated Thrombotic Microangiopathy (TA-TMA) Markers in a High-risk Cohort of Adults Undergoing Allogeneic Stem Cell Transplantation (SCT)","Inclusion Criteria:\n\n* Inclusion Criteria\n\n  1. Adult male or female, age ≥18\n  2. Undergoing allogeneic SCT at UAB for any indication and any donor source.\n  3. For patients in cohort 1: Patients deemed high-risk for developing high-risk TA-TMA as stated by any of the following criteria\\*:\n\n     1. BMI \\> 35\\[42\\]\n     2. Mismatched donor (either Haploidentical or Mismatched Unrelated donor)\\[18, 29\\]\n     3. Non-Malignant Transplant Indication (Severe Aplastic Anemia or Sickle Cell Disease)\\[18, 43\\]\n     4. Acute Lymphoblastic Leukemia (any kind)\\[18, 31\\]\n     5. African American, Hispanic, Asian or Native American Ethnicity \\[44\\]\n     6. Myeloablative Conditioning Regimen\\[18\\]\n     7. Pre-Existing Renal Disease\\*\\* (defined as any of the following: 24 Hr Creatinine Clearance \\\u003C60, baseline serum creatinine \\> 1.2, 24 hr proteinuria \\>150mg or random spot urine Protein Creatinine ratio \\> 150mg\u002Fg)\\[20, 45\\]\n     8. TBI-containing conditioning regimen \\>400cGy \\[46\\]\n     9. Prior Autologous or Allogeneic SCT\\[45\\]\n\n        * \\*Some of these criteria have been adapted from pediatric literature due to a higher number of publications in that setting and in cases where the adult data is lacking or contradictory.\n        * \\*\\*Proteinuria thresholds are obtained from KDIGO guidelines and include moderate and severe levels of proteinuria\\[47\\].\n  4. Females of childbearing potential must have a negative urine or serum pregnancy test prior to enrollment.\n  5. For patients in cohort 2: Patients who develop GVHD with any of the following characteristics and were not included in cohort 1\n\n     1. Grade III-IV aGVHD, or SR-aGVHD of any grade, whichever occurs first\n     2. Moderate to Severe cGVHD or SR-cGVHD of any grade, whichever occurs first\n  6. For patients in cohort 3: Patients included in either cohort 1 or 2 who are diagnosed with TA-TMA and receive eculizumab\n\nExclusion Criteria:\n\n* Exclusion Criteria\n\n  1. Any other active malignancy requiring treatment or with expected survival ≤1 year.\n  2. Patients with psychiatric illness or social situations that would limit compliance with the study requirements.","ALL","18 Years",{"count":19,"type":20},85,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the incidence of Transplant Associated Thrombotich Microangiopathy (TA-TMA), which is a known but underreported complication of Allogeneic Stem Cell Transplant (SCT). The main question it aims to answer is:\n\nWhat is the incidence of TA-TMA in adults undergoing SCT? How does TA-TMA diagnosis impact survival and other outcomes? Patients undergoing SCT will be eligible for this study, which will consist of collection of biological samples and standard clinical follow up.",[24,25],"Transplant Associated Microangiopathy TAM","Transplant Complication",[27,28],"Transplant Associated Thrombotic Microangiopathy","Allogeneic Stem Cell Transplant","NOT_YET_RECRUITING","2026-03-09",{"date":32,"type":33},"2026-03-11","ACTUAL",{"date":35,"type":20},"2026-07-01",{"date":37,"type":20},"2028-10",{"name":39,"class":40},"Manuel Ricardo Espinoza-Gutarra","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":21,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100619813","cardiovascular-outcomes-and-risk-evaluation-among-recipients-of-hematopoietic-stem-cell-transplantation-100619813","NCT07349498","Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation","Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation (CORE-HCT): A Prospective Multicenter Observational Study","CORE-HCT","Inclusion Criteria:\n\n* Patients who undergo hematopoietic cell transplantation at any of the participating medical centers.\n\nExclusion Criteria:\n\n* Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data.\n* Patient request to withdraw from the study.",{"count":51,"type":20},10000,"5 Years","This is a prospective, multicenter observational study for recipients of hematopoietic stem cell transplantation. Patients who underwent hematopoietic stem cell transplantation at the participating centers will be entrolled in the study. The clinical characteristics, laboratory profiles, management measures, and clinical outcomes such as post-transplant cardiovascular events will be prospectively collected.",[55,25,56],"Hematopoietic Stem Cell Transplantation","Cardiovascular Events","RECRUITING","2026-01-09",{"date":60,"type":33},"2026-01-16",{"date":62,"type":33},"2026-01-01",{"date":64,"type":20},"2036-12-31",{"name":66,"class":40},"Peking University People's Hospital",16,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":93,"locationsCount":94},"100618215","critical-illness-after-hematopoietic-cell-transplantation-100618215","NCT07328724","Critical Illness After Hematopoietic Cell Transplantation","Critical Illness Among Recipients of Hematopoietic Cell Transplantation (CARE-HCT): a Prospective, Multicenter Observational Study in China","CARE-HCT","Inclusion Criteria:\n\n* Patients who underwent hematopoietic cell transplantation at any of the participating medical centers.\n* Patients who are admitted to ICU for the management of critical illness following hematopoietic cell transplantation.\n\nExclusion Criteria:\n\n* Admitted to ICU for a reason other than critical illness (e.g., routine postoperative monitoring) and discharged within 2 days of ICU admission.\n* Unavailable in-ICU clinical outcomes or absent key baseline characteristics.\n* Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data.",{"count":77,"type":20},4000,"This is a prospective, multicenter observational trial for patients who develop critical illness after hematopoietic cell transplantation. Patients who are admitted to the intensive care unit after undergoing hematopoietic cell transplantation at the participating medical centers will be enrolled in this study. The clinical characteristics, laboratory profiles, managements, and clinical outcomes will be prospectively collected.",[80,81,82,25],"Critical Illness","Ventilated Patients","Hematopoetic Stem Cell Transplantation",[84,85,86,87,88],"hematopoietic cell transplantation","critical illness","management","prognosis","transplant complication","2025-12-27",{"date":58,"type":33},{"date":62,"type":20},{"date":64,"type":20},{"name":66,"class":40},6,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":17,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100607861","a-privacy-protecting-environment-for-child-transplants-health-related-and-genomic-data-integration-in-the-european-reference-network-100607861","NCT07194057","\"A Privacy-protecting Environment for Child Transplants Health Related and Genomic Data Integration in the European Reference Network\"","Protect_Child","Inclusion Criteria:\n\n* ● Paediatric patients (6 months to 18 years old) with liver or kidney transplant.\n\nBoth patients with de novo transplantation or in follow-up can be included in the study.\n\n* For the retrospective cohort, only patients within the first 5 years after transplantation will be included.\n* Patients and\u002For parents agreeing to participate in the study and provide consent for the obtention of clinical data and samples for genomic and methylomic analysis and the use of the information according to the protocol.\n\nExclusion Criteria:\n\n* Patients that are not being followed up in the clinical site.\n* Subjects alternating between different clinical sites. Subjects\u002FTutors that don't understand the informed consent form.\n* Subject or their legally authorized representative does not sign the informed consent document.\n* Re-transplantation or AB0-incompatible transplantation.","6 Months",{"count":104,"type":20},200,"Protect\\_Child\\_101 is an observational study to be performed in children that have undergone a liver or renal transplant.\n\nThe aim of this study is to analyse small variations in the genetic material (DNA) of transplanted children. The investigators will also study a type of chemical 'marks' called methylations, which do not change the DNA itself, but can affect how it functions. These marks can influence how certain diseases develop or how the body responds to transplantation.\n\nSpecifically, investigators seek to discover:\n\n* Whether there are genetic or epigenetic (methylation) alterations that may explain why some children develop serious diseases that require transplantation.\n* If these alterations can help us predict possible complications after transplantation, such as organ rejection, infections, organ failure, cancer development.\n\nWithin this study, data from the child's medical history will be collected. The data to be collected are demographic data (gender, age, ethnicity), clinical data, personal and family history possibly related to his\u002Fher disease, course and evolution of the disease, and complementary and laboratory examinations collected from his\u002Fher clinical history.\n\nThe only non-routine tests to be performed will be the genomic and methylomic tests. Nevertheless, these determinations will be performed on samples obtained during the child's routine care. No extra intervention is planned as part of this study.\n\nSamples and clinical data will be collected at different time points after transplantation. Schematically, collection is planned for months 0, 1, 3, 6, 12 and 24 post-transplant. In addition to these pre-established points, comprehensive data collection will be attempted when the child suffers a relevant clinical event, e.g. infection, treatment toxicity, organ rejection (post-transplant complication).",[25,107,108],"Kidney Transplant","Liver Transplant",[110,111,112,113],"observational","epigenomic analysis","genomic analysis","european health data space","2025-09-25",{"date":116,"type":33},"2025-09-26",{"date":118,"type":20},"2025-09-30",{"date":120,"type":20},"2028-01",{"name":122,"class":40},"Instituto de Investigación Hospital Universitario La Paz",4,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":134,"phases":135,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":41},"100597995","phase-4-negative-pressure-wound-therapy-in-renal-transplant-100597995","NCT07065734","NEgative prEssure Wound Therapy in Renal Transplant","NEgative prEssure Wound Therapy in Renal Transplant - NEWER Trial","NEWER","Inclusion Criteria:\n\n* All patients submitted to kidney transplant\n\nExclusion Criteria:\n\n* Pediatric patients, those requiring surgical reinterventions within the first 90 days postoperative, patients allergic to NPWT components, orthotopic transplant",{"count":133,"type":20},150,"INTERVENTIONAL",[136],"PHASE4","This is a prospective study involving patients undergoing open renal transplant. Renal transplant recipients were randomly divided into two groups: the NPWT group, which received NPWT, and the Standard group, which received standard wound dressings.",[25,139,140],"Renal Transplant","Wound Complication",[88,142,143],"renal transplant","wound complication","2025-07-10",{"date":146,"type":33},"2025-07-15",{"date":148,"type":33},"2023-01-01",{"date":150,"type":20},"2026-06-30",{"name":152,"class":40},"Centro Hospitalar De São João, E.P.E.",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":4},"100544171","genomic-medicine-in-kidney-transplantation-study-100544171","NCT06365411","GEnomic Medicine in Kidney Transplantation Study","GEM-KiT","Inclusion Criteria: All participants included in the study must be age ≥ 18 years old at time of enrolment and\n\n1. able to provide informed consent (interpreter permitted) for enrolment\n2. consenting to longitudinal follow up (can withdraw post enrolment)\n3. consenting to provide samples for biobanking, including blood, urine, faecal and\u002For kidney biopsy tissue (collected prospectively, separate to routine care)\n\nExclusion Criteria: Patients will be excluded from the study if they are\n\n1. unable (or unwilling) to provide consent, or\n2. have life-expectancy less than 6-months, or\n3. have received a haematopoietic stem cell transplant in the past 5 years.","80 Years",{"count":162,"type":20},1000,"Investigator led, prospective, observational cohort study to detect genomic features which can predict outcomes following kidney transplantation.\n\n1. Determine non-HLA genomic mismatches between donor-recipient pairs which impact kidney allograft survival following transplantation\n2. Derive polygenic risk scores on pre-transplant blood and\u002For kidney biopsy samples which predict kidney allograft dysfunction\n3. Derive polygenic risk scores on post-transplant blood and\u002For kidney biopsy samples which predict kidney allograft dysfunction",[25,165],"Kidney Transplant Rejection","2025-03-24",{"date":168,"type":33},"2025-03-28",{"date":170,"type":20},"2025-06-03",{"date":172,"type":20},"2035-01-01",{"name":174,"class":40},"Western Sydney Local Health District",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":182,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":134,"phases":185,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":199},"100497820","phase-2-oral-pooled-fecal-microbiotherapy-to-prevent-allogeneic-hematopoietic-cell-transplantation-complications-phoebus-trial-100497820","NCT05762211","Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)","A Multi-center Randomized, Double Blinded Phase IIb Trial Evaluating Oral Pooled Fecal Microbiotherapy MaaT033 to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)","Inclusion Criteria:\n\n* Age ≥ 50 years old\n* Presence of a hematologic malignancy for which an alloHCT is indicated with a reduced toxicity or reduced intensity conditioning regimen\n* Patients with polynuclear neutrophils \\> 0.5 G\u002FL\n* Patients having received wide spectrum antibiotics within the last 90 days prior to inclusion\n* Karnofsky index ≥ 70%\n* Availability of a sibling donor, an unrelated stem-cell donor or a familial haploidentical donor\n* Written informed consent\n\nExclusion Criteria:\n\n* Patients planned to receive a non-myeloablative conditioning regimen (2 Gray total body irradiation (TBI) +\u002F- purine analog, fludarabine + cyclophosphamide or equivalent)\n* Patients planned to receive a conventional myeloablative conditioning regimen (e.g. high dose cyclophosphamide and high dose TBI (≥10Gy); high dose busulfan (12.8 mg\u002Fkg IV) + high dose cyclophosphamide)\n* Patients receiving a manipulated graft (in-vitro T-cell depletion)\n* Patients planned to receive a conditioning regimen with alemtuzumab\n* Patients planned to receive alloHCT with cord blood cells\n* Patients planned to receive alloHCT from unrelated donor with \\>= 3\u002F10 HLA-mismatches\n* Patients receiving a large spectrum antibiotic at time of randomization\n* Patients planned to receive vedolizumab or abatacept for GvHD prophylaxis\n* Creatinine clearance \\\u003C30 mL\u002Fmin\n* Bilirubin or amino-transferases abnormalities contra-indicating alloHCT\n* Cardiac ejection fraction less than 40%\n* Pulmonary impairment with \\\u003C50% lung carbon monoxide diffusing capacity (DLCO)\n* Pregnancy\n* Confirmed or suspected intestinal ischemia\n* Confirmed or suspected toxic megacolon or gastrointestinal perforation\n* Any history of gastro-intestinal surgery in the past 3 months\n* Any history of chronic digestive disease (Crohn's disease, ulcerative colitis, inflammatory bowel disease or other relevant digestive condition according to physician's judgement)\n* Known allergy or intolerance to trehalose or maltodextrin\n* Patients with EBV-IgG negative serology\n* Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.\n* Vulnerable patients such as: persons deprived of liberty, persons in Intensive Care Unit unable to provide informed consent prior to the intervention.","50 Years",{"count":184,"type":20},387,[186],"PHASE2","This randomized, placebo-controlled phase IIb study (PHOEBUS trial) aims to evaluate the activity of fecal microbiotherapy MaaT033 to improve survival through the prevention of transplant-related complications in eligible alloHCT patients",[25],"2024-12-20",{"date":191,"type":33},"2024-12-27",{"date":193,"type":33},"2023-10-31",{"date":195,"type":20},"2027-02-15",{"name":197,"class":198},"MaaT Pharma","INDUSTRY",54,{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":134,"phases":208,"briefSummary":210,"conditions":211,"keywords":214,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":41},"100554032","comparison-of-clinical-value-in-the-use-of-the-fascia-lata-and-temporal-muscle-fascia-in-the-reconstruction-of-the-dura-in-the-sellar-region-100554032","NCT06493812","Comparison of Clinical Value in the Use of the Fascia Lata and Temporal Muscle Fascia in the Reconstruction of the Dura in the Sellar Region","Inclusion Criteria:\n\n1. \\*\\*Age\\*\\*: Adult patients (18 years and older).\n2. \\*\\*Surgical Requirement\\*\\*: Patients undergoing endoscopic endonasal surgery for sellar region tumors requiring reconstruction of the sellar floor to prevent postoperative cerebrospinal fluid (CSF) leaks.\n3. \\*\\*Consent\\*\\*: Patients who provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n* 1\\. \\*\\*Donor Site Pathology\\*\\*: Presence of pathology at the donor site, including trauma or previous surgical interventions.\n\n  2\\. \\*\\*Absence of Intraoperative CSF Leak\\*\\*: Patients without an intraoperative CSF leak requiring reconstruction.\n\n  3\\. \\*\\*Alternative Reconstruction Methods\\*\\*: Use of reconstruction materials other than fascia lata or temporal fascia.\n\n  4\\. \\*\\*Prior Radiation Therapy\\*\\*: Patients who have received prior radiation therapy to the operative or donor site.\n\n  5\\. \\*\\*Medical Contraindications\\*\\*: Patients with medical conditions that contraindicate the surgical procedure or participation in the study.",{"count":207,"type":20},68,[209],"NA","Study Title: Assessing the Clinical Significance of Using Fascia Lata versus Temporalis Muscle Fascia for Skull Base Reconstruction in Sellar Region\n\nObjective: The primary objective of this study is to investigate and compare the effectiveness and safety of using fascia lata and temporal muscle fascia in the reconstruction of the skull base in the sellar region. Specifically, the study aims to determine and compare the level of donor site pain between the two groups using Visual Analogue Scales (VAS). The study also aims to identify the optimal method and materials for skull base reconstruction that result in the lowest frequency of complications, thereby reducing perioperative morbidity and enabling earlier rehabilitation of patients.\n\nSubjects and Methods:\n\nStudy Design: Prospective randomized controlled trial. Population: The study will enroll 68 patients who have undergone endoscopic endonasal surgery for sellar region pathology. Patients will be divided into two groups: one group will receive skull base reconstruction using fascia lata, and the other group will receive reconstruction using temporal fascia.\n\nInterventions: In the fascia lata group, grafts will be harvested from the thigh, while in the temporal fascia group, grafts will be harvested from the temporal muscle area.\n\nMeasurements:\n\nPrimary Outcome: Donor site pain measured using Visual Analogue Scales (VAS) at various postoperative intervals (preoperative, and on the 1st, 2nd, and 3rd postoperative days, as well as 1 month and 3 months post-surgery).\n\nSecondary Outcomes: Incidence of postoperative complications such as meningitis, cerebrospinal fluid (CSF) leak, donor site infection, and other surgical complications.\n\nExpected Contribution: This research is expected to provide valuable insights into the comparative effectiveness and safety of using fascia lata versus temporal muscle fascia for skull base reconstruction. The findings could influence clinical decisions regarding the choice of graft material, potentially leading to reduced perioperative morbidity, faster patient rehabilitation, and improved overall outcomes for patients undergoing skull base surgeries.",[212,25,213],"Skull Defect","Quality of Life",[215,216,217,218,219],"CSF","fascia lata","temporal fascia","quality of life","tissue transplantation","2024-07-09",{"date":222,"type":33},"2024-07-11",{"date":224,"type":33},"2023-06-01",{"date":226,"type":20},"2033-12-01",{"name":228,"class":40},"Klinički Bolnički Centar Zagreb",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":235,"targetDuration":237,"studyType":21,"phases":4,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":41},"100542730","the-transplant-cohort-of-the-german-center-for-infection-research-100542730","NCT06346665","The Transplant Cohort of the German Center for Infection Research","Inclusion Criteria:\n\n* Consent\n* undergone transplantation of kidney, pancreas, liver, heart or stem cells\n\nExclusion Criteria:\n\n* No consent",{"count":236,"type":20},3000,"10 Years","Medical data and biological samples obtained from transplant patients are collected and managed across Germany with the help of the DZIF Transplant Cohort. The data and samples form the basis of scientific studies which investigate the connections between numerous factors influencing an organ's susceptibility to infection and organ function.",[240,25,241,242],"Infections","Transplant Failure","Immunosuppression","2024-04-22",{"date":245,"type":33},"2024-04-23",{"date":247,"type":33},"2016-01",{"date":249,"type":20},"2030-12",{"name":251,"class":40},"Technical University of Munich"]